Novo Nordisk's quarterly financial reports

Novo Nordisk's Wegovy Shows Sustained 10% Weight Loss, Heart Protection Over Four Years

May 14, 2024, 12:21 PM

Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, according to the company. The longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given a placebo 'dummy' treatment. This sustained weight loss potentially boosts the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug. A new analysis shows that the drug also provides heart protection.